Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 4
1988 3
1989 2
1990 2
1991 3
1992 6
1993 2
1994 5
1995 1
1996 6
1997 5
1998 4
1999 2
2000 4
2001 3
2002 10
2003 2
2004 4
2005 4
2006 1
2007 1
2008 2
2010 2
2011 1
2012 7
2013 7
2014 7
2015 19
2016 9
2017 14
2018 15
2019 14
2020 9
2021 16
2022 12
2023 12
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia Short Treatment (PTC) Study Group. Dinh A, et al. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. Lancet. 2021. PMID: 33773631 Clinical Trial.
The histone H3.1 variant regulates TONSOKU-mediated DNA repair during replication.
Davarinejad H, Huang YC, Mermaz B, LeBlanc C, Poulet A, Thomson G, Joly V, Muñoz M, Arvanitis-Vigneault A, Valsakumar D, Villarino G, Ross A, Rotstein BH, Alarcon EI, Brunzelle JS, Voigt P, Dong J, Couture JF, Jacob Y. Davarinejad H, et al. Among authors: joly v. Science. 2022 Mar 18;375(6586):1281-1286. doi: 10.1126/science.abm5320. Epub 2022 Mar 17. Science. 2022. PMID: 35298257 Free PMC article.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
[An update on measles].
Caseris M, Burdet C, Lepeule R, Houhou N, Yeni P, Yazdanpanah Y, Joly V. Caseris M, et al. Among authors: joly v. Rev Med Interne. 2015 May;36(5):339-45. doi: 10.1016/j.revmed.2014.10.362. Epub 2015 Jan 8. Rev Med Interne. 2015. PMID: 25579464 Review. French.
Enterococcal endocarditis management and relapses.
Garofoli N, Joly V, Le Pluart D, Hobson CA, Beaumont AL, Lariven S, Grall N, Para M, Yazdanpanah Y, Lescure FX, Peiffer-Smadja N, Deconinck L, Thy M. Garofoli N, et al. Among authors: joly v. JAC Antimicrob Resist. 2024 Mar 6;6(2):dlae033. doi: 10.1093/jacamr/dlae033. eCollection 2024 Apr. JAC Antimicrob Resist. 2024. PMID: 38449516 Free PMC article.
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
Mazouz F, Bertine M, Coppée R, Storto A, Katlama C, Landman R, Cabié A, Peytavin G, Raffi F, Yazdanpanah Y, Descamps D, Joly V, Ghosn J, Charpentier C; LAMIDOL Study Group. Mazouz F, et al. Among authors: joly v. J Antimicrob Chemother. 2023 Dec 1;78(12):2995-3002. doi: 10.1093/jac/dkad344. J Antimicrob Chemother. 2023. PMID: 37930812 Clinical Trial.
Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial.
Dinh A, Duran C, Ropers J, Bouchand F, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia short treatment (PTC) study group. Dinh A, et al. Clin Microbiol Infect. 2024 Aug;30(8):1020-1028. doi: 10.1016/j.cmi.2024.05.003. Epub 2024 May 9. Clin Microbiol Infect. 2024. PMID: 38734138 Clinical Trial.
Breakthrough Infections after Postexposure Vaccination against Mpox.
Thy M, Peiffer-Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou N, Tarhini H, Bertin C, Beaumont AL, Garé M, Le Pluart D, Perrineau S, Rahi M, Deconinck L, Phung B, Mollo B, Cortier M, Cresta M, De La Porte Des Vaux C, Joly V, Lariven S, Rioux C, Somarriba C, Lescure FX, Charpentier C, Yazdanpanah Y, Ghosn J. Thy M, et al. Among authors: joly v. N Engl J Med. 2022 Dec 29;387(26):2477-2479. doi: 10.1056/NEJMc2211944. Epub 2022 Dec 7. N Engl J Med. 2022. PMID: 36477495 No abstract available.
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration.
Pantazis N, Sabin CA, Grabar S, Van der Valk M, Jarrin I, van Sighem A, Meyer L, Carlander C, Gill J, Volny Anne A, Spire B, Tariq S, Burns F, Costagliola D, Ruiz-Burga E, Touloumi G, Porter K; CASCADE Collaboration. Pantazis N, et al. Lancet HIV. 2024 Oct;11(10):e660-e669. doi: 10.1016/S2352-3018(24)00183-8. Epub 2024 Aug 23. Lancet HIV. 2024. PMID: 39186940
215 results